Bachem Holding AG - Company Profile

Powered by

All the data and insights you need on Bachem Holding AG in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Bachem Holding AG Strategy Report

  • Understand Bachem Holding AG position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Bachem Holding AG: Overview

Select Item

Bachem Holding AG (Bachem) is a technology-based biochemical company that develops and manufactures peptides and complex organic molecules including active pharmaceutical ingredients and biochemicals for research purposes. Bachem offers products and services to the pharmaceutical and biotechnology industries. Its products are used for the treatment of various conditions such as central nervous system disorders, metabolic disorders, cancer and infectious diseases, among others. The company research products include catalog products and fluorescent dyes. Its active pharmaceutical ingredients product include NCEs, small molecules APIS and generic APIs. Its services include custom synthesis for peptides and amino acids; new chemical entities services which provides API manufacturing, process development, analytics, project management and regulatory support. The company operates production facilities in the US and Europe. Bachem is headquartered in Bubendorf, Switzerland.

 Gain a 360-degree view of Bachem Holding AG and make more informed decisions for your business Gain a 360-degree view of Bachem Holding AG and make more informed decisions for your business Find out more
Headquarters Switzerland
Address Hauptstrasse 144, Bubendorf, 4416
Website www.bachem.com
Telephone 41 61 9352333
No of Employees 2,006
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange BANB (SWF)
Revenue (2023) $642.6M 8.6% (2023 vs 2022)
EPS XYZ
Net Income (2023) XYZ 11.1% (2023 vs 2022)
Market Cap* $6.5B
Net Profit Margin (2023) XYZ 2.4% (2023 vs 2022)
* As of and is in US$
View Bachem Holding AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Bachem Holding AG premium industry data and analytics

9

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Clinical Trials

Determine Bachem Holding AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

1

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Bachem Holding AG (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Bachem Holding AG’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services
Research Chemicals: Custom Synthesis
Catalog Products New Chemical Entities:
Fluorescent dyes API Manufacturing
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Bachem Holding AG portfolio and identify potential areas for collaboration Understand Bachem Holding AG portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In March, Bachem Group signed a new framework agreement to provide large volumes of peptides.
2022 Contracts/Agreements In December, the company announced the signing of a further work order for the delivery of large volumes of peptides for a minimum total of CHF 1 billion over a five-year period from 2025-2029.
2022 Asset Purchase In October, the company agreed to acquire e an undeveloped site in Sisslerfeld (municipality of Eiken, canton of Aargau) from the company DSM in stages.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Bachem Holding AG Lonza Group Ltd Celltrion Inc Bio-Gate Ag Mymetics Corp
Headquarters Switzerland Switzerland South Korea Germany Switzerland
City Bubendorf Basel Incheon Nuernberg Epalinges
State/Province - - - Bayern -
No. of Employees 2,006 17,896 1,074 38 8
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Kuno Sommer Chairman Executive Board 2012 67
Thomas Meier Chief Executive Officer Senior Management 2020 54
Alain Schaffter Chief Financial Officer Senior Management 2020 -
Roland Schurmann Chief Operating Officer Senior Management 2020 61
Gunther Loidl Chief Technology Officer Senior Management 2015 52
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Bachem Holding AG key executives to enhance your sales strategy Gain insight into Bachem Holding AG key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?